BONUS-CERTIFICATE - NOVARTIS N/HOLCIM/GIVAUDAN/ROCHE GS Stock

Certificat

ZMACFV

CH1296731149

Market Closed - Swiss Exchange 11:20:00 2024-05-10 am EDT
117.6 CHF +1.38% Intraday chart for BONUS-CERTIFICATE - NOVARTIS N/HOLCIM/GIVAUDAN/ROCHE GS
Current month+2.98%
1 month+3.07%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change Volume
24-05-10 117.6 +1.38% 0
24-05-08 116 +0.26% 0
24-05-07 115.7 +0.96% 0
24-05-06 114.6 +1.06% 0
24-05-03 113.4 +0.27% 0

Delayed Quote Swiss Exchange

Last update May 10, 2024 at 11:20 am EDT

More quotes

Static data

Product typeBonus- and Part-Guarantee-Certificates
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
ZMACFV
ISINCH1296731149
Date issued 2023-10-20
Strike 239 CHF
Maturity 2025-10-20 (527 Days)
Parity 0.05 : 1
Emission price 100 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 117.6 CHF
Lowest since issue 100 CHF
Spread 40 CHF
Spread %0.68%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
225.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+24.12%
Consensus
  1. Stock Market
  2. Certificates
  3. ZMACFV Certificat
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW